Answers are grounded in this paper and cite their sources.
We report outcomes in a large cohort of IDH mutant glioma, providing a well-characterized historical control population for future clinical trial design. Notably, the interval between first and second recurrence (PFS2, 3.0 y) is shorter than time from diagnosis to first recurrence (PFS1, 5.7 y), evidence that these tumors clinically degenerate from an indolent course to an accelerated malignant phase. Thus, PFS2 represents a relevant outcome for trials investigating drug efficacy at recurrence.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: